Ocular Surface

EVALUATE. TREAT. SUCCEED.

MGD (Meibomian gland dysfunction) is a chronic, progressive and obstructive condition. TearScience™ enables enhanced ocular surface protection.1

Eye closeup with colors around it

Ocular Surface Health

Man taking off glasses looking tired

Evaluate

86% of patients with dry eye are affected by MGD2 and our TearScience portfolio can help you evaluate for it.
ECP and patient talking

Treat

Treating MGD optimizes the tear film, the first refractive surface of the eye.3
Woman with surfing suit

Succeed

Read articles and resources about MGD.

Eye health starts at the surface

MGD is a chronic, progressive and obstructive condition. Approximately 1 in 5 patients with MGD are asymptomatic.4

  • Over 745 million people worldwide suffer from Dry Eye5
  • 63% of pre-cataract surgical patients had a sign of MGD6
  • 60% of contact lens wearers have meibomian gland dysfunction (MGD)7
  • 80% of glaucoma patients taking long-term antiglaucoma medications8

MGD in the contact lens patient

Case study: contact lens discomfort

ASCRS cornea committee

ASCRS Logo

Consensus based clinical practice guidelines.

LipiFlow patient video

Patient testimonial

Join Our 40,000+ Community of Eye Health Professionals

Sign-up to receive exclusive access to the latest learnings, events, and more.

REFERENCES

  1. 2019 ASCRS Cornea Clinical Committee Guidelines
  2. 13. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012; 31(5): 472-478.
  3. Willcox MDP et al. TFOS DEWS II Tear Film Report. The Ocular Surface. 2017; 15:366-403
  4. Viso E, et al. Prevalence of asymptomatic and symptomatic Meibomian Gland Dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci. 2012; 53(6): 2601–2606. doi: 10.1167/ iovs.11-9228
  5. Market Scope 2019 Dry Eye Report.
  6. Trattler WS, Majmudar PA, Donnenfeld ED, McDonald MB, Stonecipher KB, Goldberg DF. The prospective health assessment of cataract patient (PHACO) study: the effect of dry eye. Clin Ophthalmol. 2017; 11: 1423-1430.
  7. Blackie C, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Current Opinion in Ophthalmology. 2015; 26(4):306 13.
  8. Uzunosmanoglu E, at al. Meibomian gland dysfunction in patients receiving long-term glaucoma medications. Cornea. 2016; 35(8): 1112-1116. doi:10.1097/ico.0000000000000838.

PP2023OTH5911

Johnson & Johnson MedTech
We support the AdvaMed Code of Ethics on interacting with Healthcare Professionals.
Advamed Logo
Overview
Useful Links
Legal
Additional Information
© Johnson & Johnson and its affiliates 2024. All rights reserved. This site is published by Johnson & Johnson Vision Care, Inc. and Johnson & Johnson Surgical Vision, Inc., which are solely responsible for its content.

This product information is intended for use by customers and healthcare professionals in the United States only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside the United States, and the information from other sites you visit may not be appropriate for use in the United States.

Third party trademarks used herein are trademarks of their respective owners.

Vision Made Possible™
PP2023OTH5699 v3